

PAULO FELIPE IZIQUE GOIOZO

**ESTUDO COMPARATIVO DOS EFEITOS DO VENENO BRUTO DE SERPENTES
Crotalus durissus terrificus (LAURENTI, 1768) E *Crotalus durissus collilineatus*
(AMARAL, 1926) EM LESÕES TECIDUAIS OCASIONADAS PELA INTOXICAÇÃO
EXPERIMENTAL EM RATOS WISTAR**

PAULO FELIPE IZIQUE GOIOZO

**ESTUDO COMPARATIVO DOS EFEITOS DO VENENO BRUTO DE SERPENTES
Crotalus durissus terrificus (LAURENTI, 1768) E *Crotalus durissus collilineatus*
(AMARAL, 1926) EM LESÕES TECIDUAIS OCASIONADAS PELA INTOXICAÇÃO
EXPERIMENTAL EM RATOS WISTAR**

Tese apresentada Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade do Oeste Paulista, como parte dos requisitos para obtenção do título de Doutor – Área de concentração: Fisiopatologia e Saúde Animal

Orientadora:
Prof^a Dra. Rosa Maria Barili Nogueira

636.089 G615e	<p>Goiozo, Paulo Felipe Izique. Estudo comparativo dos efeitos veneno bruto de serpentes <i>Crotalus durissus terrificus</i> (Laurenti, 1768) e <i>Crotalus durissus collilineatus</i> (Amaral, 1926) em lesões teciduais ocasionadas pela intoxicação experimental em ratos wistar / Paulo Felipe Izique Goiozo. – Presidente Prudente, 2018. 57f.: il.</p> <p>Tese (Doutorado em Fisiopatologia e Saúde Animal) - Universidade do Oeste Paulista – Unoeste, Presidente Prudente, SP, 2018. Bibliografia. Orientador: Profª Dra. Rosa Maria Barili Nogueira</p> <p>1. Lesões teciduais. 2. Veneno Crotálico. 3. Histopatologia. I. Título.</p>
------------------	---

PAULO FELIPE IZIQUE GOIOZO

**ESTUDO COMPARATIVO DOS EFEITOS DO VENENO BRUTO DE SERPENTES
Crotalus durissus terrificus (LAURENTI, 1768) E *Crotalus durissus collilineatus*
(AMARAL, 1926) EM LESÕES TECIDUAIS OCASIONADAS PELA INTOXICAÇÃO
EXPERIMENTAL EM RATOS WISTAR**

Tese apresentada Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade do Oeste Paulista, como parte dos requisitos para obtenção do título de Doutor. - Área de Concentração: Fisiopatologia e Saúde Animal

Presidente Prudente, 03 de Dezembro de 2018

BANCA EXAMINADORA

Prof^a. Dra. Rosa Maria Barili Nogueira (Orientadora)
Universidade do Oeste Paulista – Unoeste
Presidente Prudente-SP

Prof^a. Dra. Elisângela Olegário da Silva
Instituição: Universidade do Oeste Paulista - Unoeste
Presidente Prudente - SP

Prof^a. Dra. Cecília Braga Laposy Santarém
Instituição: Universidade do Oeste Paulista - Unoeste
Presidente Prudente - SP

Prof^a. Dra. Karina Maria Basso
Instituição: Centro Universitário Filadélfia - Unifil
Londrina - PR

Prof. Dr. Raimundo Alberto Tostes
Instituição: Universidade Federal do Paraná – UFPR – *Campus Jandáia do Sul* - PR
Jandáia do Sul - PR

DEDICATÓRIA

A **Deus**, pois nos permite superar e ultrapassar barreiras.

Aos meus pais **Sagramor de Fátima Izique Goiozo** e **José Paulo Goiozo** pelo incentivo, exemplo de vida e amor incondicional.

Aos meus filhos **Paulo Felipe Izique Goiozo Filho** e **Isabella da Silva Freitas Goiozo** pela compreensão e amor incondicional.

À **Débora Reis Leal de Lima**, pela dedicação, amor, incentivo, companheirismo, amizade e cumplicidade em todos os momentos.

À **Prof.^a Dra. Rosa Maria Barili Nogueira** pelo exemplo de vida acadêmica e incentivo.

AGRADECIMENTOS

À Prof^a. Dra. Rosa Maria Barili Nogueira pela orientação e pelas inúmeras oportunidades.

À Universidade do Oeste Paulista pelo suporte financeiro e estrutural.

À professora Elisângela Olegário da Silva pelo apoio em várias etapas deste trabalho.

À professora Adriana Falco de Brito e às, antes orientadas e agora colegas de profissão, Liliane Giroto Pereira e Elaine Carrion de Fares pelo apoio nas coletas e processamento de materiais biológicos.

À Prof.^a Gláucia Prado Kanashiro pelo apoio e oportunidade.

Aos técnicos do Laboratório de Patologia Animal da Universidade do Oeste Paulista Marcos Roberto Ramos e Cleonice Trevizan pelo apoio no processamento do material biológico.

“Há três virtudes essenciais para o equilíbrio e sucesso na vida...

-Ensinar o que sabe...

-Praticar o que ensina...

-Questionar o que se ignora...

” (Adaptado por Mário Sérgio Cortella do pensador britânico Beda – Século. VIII)

RESUMO

Estudo comparativo dos efeitos do veneno bruto de serpentes *Crotalus durissus terrificus* (Laurenti, 1768) e *Crotalus durissus collilineatus* (Amaral, 1926) em lesões teciduais ocasionadas pela intoxicação experimental em ratos wistar

Crotalus durissus é a única espécie do gênero que habita o Brasil e é responsável pelo maior número de mortes por acidentes ofídicos. O veneno crotálico é uma mistura complexa de proteínas ativas, enzimas, toxinas e polipeptídeos. Esses componentes possuem ações neurotóxicas, miotóxicas, nefrotóxicas, hepatotóxicas e coagulantes, no entanto, estudos mostram variações no efeito do veneno. O objetivo deste estudo foi quantificar, qualificar e diferenciar as lesões teciduais sistêmicas produzidas pelo veneno das serpentes *Crotalus durissus terrificus* e *Crotalus durissus collilineatus* em ratos Wistar. Utilizou-se ratos machos Wistar (n = 60). Os animais foram alocados em três grupos (n = 20 cada): Grupo Controle (GC); Grupo C. durissus terrificus (CdtG); e, grupo de serpentes C. durissus collilineatus (CdcG). Após a eutanásia, cérebro, pulmão, coração, fígado, jejuno, cólon, baço, rins, músculo esquelético e testículos foram coletados para análises histopatológicas e um escore de lesão por animal foi estabelecido. No sistema nervoso central, escores significativos das lesões ($p < 0,05$) foram observados no CdcG e no CdtG. O maior escore lesional foi observado no CdtG. No tecido muscular, o CdcG apresentou maior escore de lesão no coração, enquanto no músculo esquelético o maior escore foi encontrado no CdtG. No rim, lesões significativas foram observadas no CdcG e no CdtC com o escore lesional médio mais alto no CdcG. O maior escore de lesão hepática foi no CdtG. No pulmão, maior lesional elevado foi observado apenas no CdcG. No baço, baixos escores lesionais foram evidenciados. Nos intestinos, o cólon apresentou baixos escores de lesão, porém diferenças significativas ($p < 0,05$) foram observadas. O único órgão que apresentou diferença significativa ($p < 0,05$) entre os três grupos foi o jejuno. Nos testículos escores lesionais significativos foram encontrados em ambos os grupos. Nossos resultados mostram que o veneno crotálico tem um efeito deletério em todos os sistemas orgânicos. Ao abordar um paciente com suspeita de picada de cascavel, o clínico deve considerar variações nos sinais clínicos em virtude da composição, bem como diferenças no desempenho de cada subespécie em diferentes tecidos. Os dados obtidos em nosso estudo fornecem subsídios para novas pesquisas sobre a toxicidade do veneno crotálico das diferentes subespécies do gênero *Crotalus durissus*.

Palavras-chave: Escores Lesionais, Cascavéis e Histopatologia

ABSTRACT

Comparative study of the effects of the raw venom of snakes *Crotalus durissus terrificus* (Laurenti, 1768) and *Crotalus durissus collilineatus* (Amaral, 1926) on tissue injury caused by experimental intoxication in wistar rats

Crotalus durissus is the only species of the genus that inhabits Brazil and is responsible for the highest number of deaths from ophidian accidents. Crotalic venom is a complex mixture of active proteins, enzymes, toxins, and polypeptides. These components have neurotoxic, myotoxic, nephrotoxic, hepatotoxic and coagulant actions, however, studies show variations in the effects of the poison. The objective of this study was to quantify, characterize and differentiate the systemic tissue lesions produced by venom of *Crotalus durissus terrificus* and *Crotalus durissus collilineatus* snakes in Wistar rats. Male Wistar rats (n = 60) were used. The animals were allocated into three groups (n = 20 each): Control Group (CG); *C. durissus terrificus* group (CdtG); and *C. durissus collilineatus* group (CdcG). After euthanasia, brain, lung, heart, liver, jejunum, colon, spleen, kidneys, skeletal muscle and testes were collected for histopathological analysis and a lesion score per animal was established. In the central nervous system, significant lesion scores (p <0.05) were observed in the CdcG and CdtG. The highest lesion score was observed in the CdtG. In muscle tissue, the CdcG presented a higher lesion score in the heart, whereas in the skeletal muscle the highest score was found in the CdtG. In the kidney, significant lesions were observed in the CdcG and CdtC with the highest mean lesion score in the CdcG. The highest hepatic injury score was in the CdtG. In the lungs, a higher lesion score was observed only in the CdcG. In the spleen, low lesion scores were evidenced. In the intestines, the colon presented low lesion scores, but significant differences (p <0.05) were observed. The only organ that presented significant differences (p <0.05) between the three groups was the jejunum. In the testis, significant lesion scores were found in both groups (p<0,05). Our results show that crotalic venom has a deleterious effect on all organic systems. When addressing a patient with a suspected rattlesnake bite, the clinician should consider variations in clinical signs by virtue of the composition as well as differences in the performance of each subspecies in different tissues. The data obtained in our study provide subsidies for new research on the toxicity of crotalic venom of the different subspecies of the genus *Crotalus durissus*.

Keywords: Lesion Score, Rattlesnake and Histopathology.

SUMÁRIO

ARTIGO 1	Comparative study of tissue lesions caused by <i>Crotalus durissus terrificus</i> and <i>Crotalus durissus collilineatus</i> venoms in Wistar rats.....	10
ARTIGO 2	Comparative study of tissue lesions caused by <i>Crotalus durissus terrificus</i> and <i>Crotalus durissus collilineatus</i> venoms in Wistar rats.....	26
ANEXO 1	PARECER FINAL DA COMISSÃO DE ÉTICA E USO DE ANIMAIS (CEUA/UNOESTE).....	37
ANEXO 2	TERMO DE DOAÇÃO DOS VENENOS UTILIZADOS NO ESTUDO.....	38
ANEXO 3	NORMAS DE PUBLICAÇÃO DOS PERIÓDICOS.....	39

ARTIGO 1

1 COMPARATIVE STUDY OF TISSUE LESIONS CAUSED BY *CROTALUS*
 2 *DURISSUS TERRIFICUS* AND *CROTALUS DURISSUS COLLILINEATUS* VENOMS
 3 IN WISTAR RATS.¹

4 Paulo Felipe Izique Goiozo¹, Liliane Giroto Pereira¹, Elisângela Olegário da Silva²,
 5 Elaine Carrion de Fares², André Carrion de Fares Pinto³, Flávia Lima de Godoy³,
 6 Adriana Falco de Brito¹ & Rosa Maria Barilli Nogueira¹

7 ¹ Postgraduate Program in Animal Physiopathology and Health – Universidade do
 8 Oeste Paulista – Presidente Prudente – São Paulo State - Brazil.

9 ² Veterinary Medicine Course, Universidade do Oeste Paulista - Presidente
 10 Prudente, São Paulo State, Brazil.

11 ³ Medicine School, Universidade do Oeste Paulista - Presidente Prudente, São Paulo
 12 State, Brazil.

13 * Corresponding author: Postgraduate Program in Animal Physiopathology and
 14 Health – Universidade do Oeste Paulista. Rodovia Raposo Tavares, Km 572 – Bairro
 15 Limoeiro - Presidente Prudente – São Paulo State – Brazil – Zip Code: 19.067-175.

16

17

¹ Artigo redigido de acordo com as normas do periódico Acta Veterinaria.
 Disponível em: <http://www.actaveterinaria.rs/page/5>

18 **SUMMARY**

19 *Crotalus durissus* snakes are responsible for the highest number of snakebite deaths
20 in Brazil and countries in South and Central America. Crotalic venom is a complex
21 mixture of active proteins, enzymes, toxins, and polypeptides. These components
22 have neurotoxic, myotoxic, nephrotoxic, hepatotoxic and coagulant actions, however,
23 studies show variations in the effects of the poison. The objective of this study was to
24 quantify the systemic tissue lesions produced by venom of *Crotalus durissus*
25 *terrificus* and *Crotalus durissus collilineatus* snakes in Wistar rats. Wistar males were
26 divided into three groups (n = 20 each): Control Group (CG); *C. durissus terrificos*
27 group (CdtG); and *C. durissus collilineatus* group (CdcG). After euthanasia, brain,
28 lung, heart, liver, jejunum, colon, spleen, kidneys and skeletal muscle were collected
29 for histopathological analysis and a lesion score per animal was established.
30 Circulatory changes, inflammatory, degenerative and necrotic processes were found
31 in the tissues analyzed. Cdt venom presented higher lesion scores in brain, skeletal
32 muscle, liver and spleen. More severe lesions caused by Cdc venom were found in
33 the heart, kidneys, lung, jejunum, and colon. Our results show that crotalic venom
34 has a toxic effect on all organic systems. When addressing a patient with a
35 suspected of rattlesnake bit, the clinician should consider variations in clinical signs
36 by virtue of the composition as well as differences in the performance of each
37 subspecies in different tissues. The data obtained in our study provide subsidies for
38 new research on the toxicity of crotalic venom of the different subspecies of the
39 genus *Crotalus durissus* as well as other vipers with similar venom composition.

40 **KEY WORDS:** Lesion Score, Rattlesnake and Histopathology.

41

42

43 INTRODUCTION

44 *Crotalus durissus* is responsible for the highest number of deaths due to ophidian
45 accidents, constituting a problem both in public health and animal production, with
46 more than 27.000 notifications registered in Brazil in 2014 [1-3]. This species is
47 divided into seven subspecies of which *Crotalus durissus terrificus* (Cdt) and *Crotalus*
48 *durissus collilineatus* (Cdc) stand out as they inhabit areas of greater population
49 density in Brazil [4-6]. Crotalic venom is a complex mixture of active proteins,
50 enzymes, toxins, and polypeptides. These components have neurotoxic, myotoxic,
51 nephrotoxic, hepatotoxic and coagulant actions, however, studies show variations in
52 the effect of venom according to subspecies, diet, habitat and the age of the snakes
53 [3, 7-10].

54 The aim of this study was to quantify and qualify the systemic tissue lesions
55 produced by the venom of the snakes *Crotalus durissus terrificus* and *Crotalus*
56 *durissus collilineatus* in Wistar rats.

57

58 MATERIALS AND METHODS

59 *Ethics Statements*

60 This research was approved by the Ethics Committee and for Use of Animals (CEUA)
61 of our institution in accordance with the National Council of Control and Animal
62 Experimentation of Brazil (CONCEA), protocol n° 3220.

63 *Animals*

64 Sixty six-month-old male Wistar rats (350g) were used in the present study. The
65 animals were housed in a ventilated environment in clean and sanitized cages with
66 free access to food and water *ad libitum*, under a 12-h light: 12-h dark cycle and
67 controlled temperature (22±2 C°).

68

69 *Venoms*

70 *Crotalus durissus terrificus* and *Crotalus durissus collilineatus* lyophilized samples
71 were kept frozen at -20°C until the moment of use and reconstitution was performed
72 at the concentration of 1.0mg / kg with saline solution 0.9%, according previous
73 studies [12]. The venom management was in accordance with *WHO Guidelines for*
74 *the Production Control and Regulation of Snake Antivenom Immunoglobulins* [13].

75 *Experimental Procedures*

76 The animals were submitted to the following treatments (20 rats/treatment): Control
77 group (CG) inoculated with saline solution 0,9% intramuscularly; *C. durissus terrificus*
78 group (CdtG) inoculated with 1,0mg/Kg of venom intramuscularly; and, *C. durissus*
79 *collilineatus* group (CdcG) inoculated with 1,0mg/Kg of venom intramuscularly. The
80 animals remained intoxicated for six hours according to previous clinical studies [14]
81 and were subsequently submitted to inhalation anesthesia with isoflurane to induce
82 unconsciousness verified by the absence of tail, interdigital and corneal reflexes and
83 then euthanized by exsanguination [15].

84 *Histological Assessment*

85 After euthanasia, samples of brain, lung, heart, liver, jejunum, colon, spleen, kidneys,
86 and skeletal muscle were collected and fixed in 10% buffered formalin solution,
87 dehydrated in alcohols and embedded in paraffin. Sections of 3 µm were stained with
88 Hematoxylin and Eosin (H&E), Masson trichrome and Periodic Acid-Schiff (PAS) for
89 histopathological evaluation.

90 Histopathological analyzes were performed throughout the histological section. A
91 histological score adapted from previous studies [16-18] was used to compare
92 morphological changes and lesions between the treatments (Table 1).

93 **Table – 1:** Lesion score-endpoint* used to evaluate histologic lesions in rats
 94 experimentally inoculated with *Crotalus durissus terrificus* or *Crotalus durissus*
 95 *collilineatus* venom
 96

Tissue	Type of Lesion	Severity Factor	Maximal Score
Brain	Red Neuron	3	45
	Gliosis	2	
	Central Chromatolysis	3	
	Malacia	3	
	Wallerian degeneration	2	
	Congestion	2	
Lung	Alveolar edema	2	21
	Congestion	2	
	Interstitial inflammatory infiltrate	2	
	Hemorrhage	1	
Heart	Congestion	2	45
	Inflammatory infiltrate	2	
	Interstitial edema	2	
	Hemorrhage	2	
	Myocyte degeneration	2	
	Myocyte hypertrophy	2	
	Necrosis	3	
Liver	Apoptosis	2	36
	Cytoplasmic vacuolation	1	
	Disorganization of hepatocytes cords	1	
	Inflammatory infiltrate	2	
	Megalocytosis	2	
	Nuclear vacuolations	1	
	Necrosis	3	
	Jejunum	Cubic enterocyte	
Enterocyte vacuolation		2	
Interstitial edema		2	
Lymphatic vessel dilatation		1	
Villi apical necrosis		3	
Villus fusion		2	
Villus flattening		2	
Colon	Cubic enterocyte	2	24
	Interstitial edema	2	
	Lymphatic vessel dilatation	1	
	Necrosis	3	
Spleen	Apoptosis	1	36
	Germinal center depletion	1	
	Germinal center proliferation	1	
	Histiocytosis	2	
	Inflammatory Infiltrate	2	
	Mitosis	1	
	Necrosis	3	
	Reactivity	1	
Kidneys	Congestion	1	33
	Cytoplasmic vacuolation	1	
	Inflammatory infiltrate	2	
	Hemorrhage	2	
	Necrosis	3	
	Nuclear vacuolation	1	
	Tubular casts	1	
Skeletal muscle	Congestion	2	45
	Inflammatory infiltrate	2	
	Interstitial edema	2	
	Hemorrhage	2	
	Myocyte degeneration	2	
	Myocyte hypertrophy	2	
	Necrosis	3	

97 *The score for each lesion was obtained by multiplying the severity factor by the
 98 extent of the lesion. The organ score was then obtained through the sum of each
 99 lesion score. Severity factor (degree of severity): 1-mild lesions, 2-moderate lesions
 100 and 3-severe lesions. The extent of each lesion (intensity or observed frequency)
 101 was evaluated and scored as 0-no lesion, 1-low extent (25% of the tissue affected),
 102 2-intermediate extent (50% of the tissue affected) and 3- large extent (75% or more
 103 of the tissue affected).

104 *Statistical Analysis.*

105 The normality and homogeneity of data were previously analyzed using the Shapiro-
 106 Wilk and Bartlett tests respectively. When these two assumptions were met, the
 107 analysis of variance (ANOVA) with Duncan's test contrast was used to determinate
 108 statistical differences between groups. Statistical significance was set at $P > 0.05$ [19].

109

110 **RESULTS**

111 Six hours after venoms exposure, the rats presented discrete to severe histological
 112 lesion compared with the control (Table 2).

113 **Table – 2:** Lesion scores obtained in different tissues of Wistar rats inoculated
 114 with *Crotalus durissus collilineatus* or *Crotalus durissus terrificus* venom.

Tissue	Control	CdcG	Cdt
Brain	3.04±1.62 ^a	9.63±6.01 ^b	14.10±0.85 ^b
Skeletal muscle	0.70±0.97 ^a	12.0±4.51 ^b	14.88±2.2 ^b
Heart	6.90±1.65 ^a	13.58±3.74 ^b	11.75±3.40 ^b
Kidney	2.42±0.60 ^a	13.78±3.58 ^b	11.50±2.46 ^b
Liver	3.68±0.67 ^a	10.63±1.46 ^b	13.72±2.96 ^b
Lung	4.20±1.70 ^a	9.05±2.14 ^b	3.60±2.01 ^a
Spleen	1.12±0.34 ^a	3.35±0.93 ^b	3.47±1.12 ^b
Jejunum	0.10±0.30 ^a	10.47±2.96 ^b	7.47±2.91 ^c
Colon	0.85±0.93 ^a	4.88±2.11 ^b	4.64±2.34 ^b

115 Different letters on the same line (a,b and c) denote significant differences ($p < 0.05$);
 116 **CdcG:** *Crotalus durissus collilineatus* group; **CdtG:** *Crotalus durissus terrificus*
 117 group.

118

119 In the central nervous system, significant lesion scores ($p < 0.05$) were observed in
 120 the CdcG and CdtG groups in relation to the control group. The lesions presented a
 121 discrete distribution characterized by Wallerian degeneration, red neurons, central
 122 chromatolysis, gliosis and congestion (Figure 1A).

123 In the muscle tissue (heart and skeletal muscle), the CdcG group presented a higher
124 lesional score-endpoint in the heart whereas in the skeletal muscle tissue the highest
125 score was found in the CdtG group. In the CdcG and CdtG groups the lesions in the
126 heart observed were inflammatory infiltrate with mononuclear predominance,
127 interstitial edema, hemorrhagic foci, degeneration and myocyte necrosis with discrete
128 distribution (Figures 1B and 1C).

129 In the renal parenchyma, the most frequent lesions were degeneration and tubular
130 necrosis followed by circulatory changes (vascular congestion and hemorrhage) and
131 nuclear vacuolization (Figure 1D).


132 In the liver, the main histological lesions were cytoplasmic vacuolization, hepatocyte
133 cord disruption, nuclear vacuolization and coagulation necrosis (Figure 1E). In the
134 lungs, an elevated lesional score-endpoint was observed only in the Cdc group. The
135 changes with moderate distribution in the CdcG constituted circulatory changes such
136 as vascular congestion and hemorrhage (Figure 1F).

137 Low lesion score-endpoints were observed in the spleen, however, significant
138 differences ($p < 0.05$) were observed in the CdcG and CdtG groups in relation to the
139 control group. Only germinal center depletion was evidenced with discrete intensity
140 (Figure 1G).

141 In the intestines, the colon presented low lesion scores, however, significant
142 differences ($p < 0.05$) were observed between the CdcG and CdtG when compared to
143 the CG. In this organ, only necrosis and dilatation of lymphatic vessels with discrete
144 distribution were observed in both inoculated groups (Figure 1H). In this experiment,
145 the only organ that presented significant differences ($p < 0.05$) between the three
146 groups was the jejunum. The CdcG group presented a higher lesional score-endpoint
147 with lesions in the villi (apical necrosis, flattening and fusion of villi), dilatation of

148 lymphatic vessels and cubic enterocytes. In the CdtG group, only villous changes
 149 and dilation of lymphatic vessels were observed (Figure 1I).

150



151

152 **Figure 1:** Photomicrographs of different tissues of Wistar rats inoculated with
 153 snake venom *Crotalus durissus* sp. (H&E, Bar 100 μ m) **(A)** Brain (CdtG)
 154 showing red neurons (black arrow); **(B)** Heart (CdcG). Hemorrhagic areas
 155 (black arrow); **(C)** Skeletal muscle (CdtG). Interstitial mononuclear inflammatory
 156 infiltrate (black arrow) and fibers with coagulation necrosis (red arrow); **(D)**
 157 Kidney (CdcG). Areas with hemorrhage and tubular cells with pyknotic nuclei
 158 and karyolysis; **(E)** Liver (CdtG) showing marked cytoplasmic vacuolization and
 159 pyknotic nuclei; **(F)** Lung (CdcG) with marked circulatory changes (black arrow);
 160 **(G)** Spleen (CdtG) with discrete lymphoid germinal center depletion (black
 161 arrow); **(H)** Large intestine (CdcG) showing dilatation of lymphatic vessel (black
 162 arrow); **(I)** Small intestine (CdcG) showing fusion of the villi (black arrow).

163 **CdcG** = *Crotalus durissus collilineatus* group; **CdtG** = *Crotalus durissus*
 164 *terrificus* Group.

165

166

167 **DISCUSSION**

168 Studies involving the toxic effects of venom have been performed in isolated organs
169 such as kidney and liver [7,9,20,21], or only in fractions such as crotoamine, crotoxin
170 or LAAO (L-amino acid oxidase) [8,10,22-25].

171 Crotoamin is a major component of crotoalic venom and has demonstrated toxicity and
172 proinflammatory activity nervous and systemic [24]. In addition, preliminary studies
173 indicate that thrombin-like enzyme isolated from *Crotalus durissus terrificus* venom
174 induces in vivo neurotoxicity resulting morphological and behavioral in brain tissue
175 [26]. These effects are consistent with the tissue lesions found. The *C.d. terrificus*
176 venom resulted in late-to-endpoint scores above those of *C. d. collilineatus*. This
177 corresponds to the low peripheral toxicity caused by the action of the crotoamine-
178 negative fraction present in the venom of *C. d. collilineatus* where this fraction is
179 responsible for analgesia in cases of accidents with this subspecies [21]. The
180 muscular lesions in crotoalic accidents are caused by the association of crotoxin-simile
181 and phospholipase A2 (PLA2), being present in the venom of all subspecies [6,8].
182 Crotoamine also acts on muscle degradation by presenting the capacity of cellular
183 penetration and modifying cellular functions, mainly from mitochondria [28,29]. In our
184 study, we demonstrated muscle lesions with higher lesion scores in animals
185 inoculated with the venom of *C. d. collilineatus*, although elevated lesion scores were
186 also shown in animals inoculated with venom of *C. d. terrificus*.

187 Controversial findings of the inoculated venoms were observed in the heart, in which,
188 greater lesions were seen in the animals inoculated with venom of *C. d. collilineatus*.
189 These results indicate that cardiac lesions could be associated with lung lesions,
190 since only the animals of the CdcG group demonstrated alterations in the lungs.
191 Pulmonary changes in ophidian accidents are poorly described in the literature,

192 studies with the subspecies *C.d. cascavela* have shown that the action of crotoamine
193 with PLA2 can induce circulatory changes in the lungs [29]. Our results reveal the
194 differences between the subspecies studied suggesting further studies are necessary
195 on the respiratory dynamics in the crotalic poisoning of different subspecies.

196 In the liver, hepatotoxicity from the venom of *C. d. terrificus* occurs as a consequence
197 of vascular lesions resulting in increased serum hepatic enzymes and structural
198 damage [9]. The results obtained in the present study indicate that the difference in
199 venom composition may have direct effects on hepatocytes, since the CdtG
200 presented a higher lesional score-endpoint can due the greater intensity in the
201 injured hepatocytes. Our results associated with previous studies may suggest that
202 these morphological changes are due to the actions of crotoamine in mitochondria,
203 which depending on the concentration and time of exposure may induce apoptosis or
204 result in cell death through oxidative stress [22,28,30].

205 The majority of deaths due to crotalic accidents are attributed to acute renal failure
206 caused by venom. Studies indicate that acute renal failure results from the effects of
207 crotoamine on the glomeruli together with changes in renal hemodynamics and
208 vascular changes with decreased blood flow [20,21]. In both inoculated groups, high
209 lesion scores were observed, being more pronounced in the animals inoculated with
210 *Crotalus durissus collilineatus* venom. Studies have shown that *Crotalus durissus*
211 *collilineatus* venom induces direct and indirect morphofunctional changes in the
212 kidneys due to the synergism of crotoxin and PLA2 and the release of other
213 substances such as myoglobin [31]. As shown in our results, there are significant
214 differences between the subspecies, indicating that the composition of the venom
215 directly influences the renal damages.

216 As described previously, crotalic venom has a broad performance in different organ
217 systems due to its complex composition, which results in nonspecific clinical signs
218 that make diagnosis difficult [3]. This study reports splenic and intestinal
219 morphological changes caused by crotalic poisoning by the subspecies *C. d.*
220 *terrificus* and *C. d. collilineatus* previously not described in the literature, noting
221 significant differences between subspecies were detected in the small intestine. In
222 the spleen, we may suggest that the changes are due to the suppressive action of
223 crotoamine demonstrated by previous studies [32].

224

225 **CONCLUSION**

226 In conclusion, our results show that crotalic venom has a deleterious effect on all
227 organ systems. When approaching a patient with a suspected rattlesnake bite, the
228 medical clinician should consider variations in clinical signs by virtue of composition
229 as well as differences in the performance of each subspecies in different tissues. The
230 data obtained in our study provide subsidies for new research on the toxicity of
231 crotalic venom of the different subspecies of the genus *Crotalus durissus*.

232

233 **ACKNOWLEDGEMENTS**

234 This research received financial support from the Universidade do Oeste Paulista
235 (Protocol No. 3220). The venoms used in this study were provided by the
236 Herpetological Collection of the Center for Biological Studies and Research of the
237 Pontifical Catholic University – Goiás State - Brazil (Document no.º 01/2018)

238

239

240

241 **REFERENCES**

- 242 1. Brasil. 2015. Óbitos por Acidentes por Serpentes. Brasil, Grandes Regiões e
243 Unidades Federativas. 2000 a 2013. *Ministério da Saúde*.
244 [Http://portalarquivos2.saude.gov.br/images/pdf/2014/julho/10/Tabela-08---](http://portalarquivos2.saude.gov.br/images/pdf/2014/julho/10/Tabela-08---OBITOS---serpente---2000-a-2013---21-05-2014.pdf)
245 [OBITOS---serpente---2000-a-2013---21-05-2014.pdf](http://portalarquivos2.saude.gov.br/images/pdf/2014/julho/10/Tabela-08---OBITOS---serpente---2000-a-2013---21-05-2014.pdf)
- 246 2. Estrada JS, Quintana C, Castillo L, Vargas: Accidente ofídico en animales de
247 pastoreo : acercamiento epidemiológico , clínico y de manejo. *Rev Med Vet*
248 2014, 27: 10–20.
- 249 3. Tokarnia CH, Peixoto PV: A importância dos acidentes ofídicos como causa
250 de moetes em bovinos no Brasil. *Pesqui Vet Bras* 2006, 26: 55–68.
- 251 4. Gomes F, Andrade D, Ávila-Pires TC: Herpetologia Brasileira. *Rev Herp Bras*
252 2013, 2: 24.
- 253 5. Uetz, P: The Reptile Database: <http://www.reptile-database.org>
- 254 6. Boldrini-França J, Corrêa-Netto C, Silva MMS, Rodrigues RS, De La Torre P,
255 Pérez A, Soares AM, Zingali RB, Nogueira RA, Rodrigues VM, Sanz L,
256 Calvete JJ: 2010. Snake venomics and antivenomics of *Crotalus durissus*
257 subspecies from Brazil: Assessment of geographic variation and its implication
258 on snakebite management. *J Proteomics* 2010. 73: 1758–1776.
- 259 7. Albuquerque PLMM, Jacinto CN, Junior GBS, Lima JB: Review acute kidney
260 injury caused by crotalus and bothrops snake venom: a review of
261 epidemiology , clinical manifestations and treatment. *Rev Inst Med*
262 *Trop Sao Paulo* 2013, 55: 295–301.
- 263 8. Dos-santos MC: Crotoxina e crotoxina-simile isoladas de venenos de
264 subespécies de *Crotalus durissus* e suas múltiplas atividades. *Sci Amazon*
265 2014, 3: 102–115.

- 266 9. França RF, Vieira RP, Ferrari EF, Souza RA, Osorio RAL, Prianti-Jr ACG,
267 Hyslop S, Zamuner SR, Cogo JC, Ribeiro W: Acute hepatotoxicity of *Crotalus*
268 *durissus terrificus* (south american rattlesnake) venom in rats. *J Venom Anim*
269 *Toxins incl Trop Dis* 2009, 15: 61–78.
- 270 10. Lourenço A, Fernanda C, Creste Z, Curtolo L, Barros D, Delazari L, Pimenta
271 DC, Barraviera B, Seabra R: Toxicon Individual venom profile of *Crotalus*
272 *durissus terrificus* specimens from a geographically limited region:
273 Crotamine assessment and captivity evaluation on the biological activities.
274 *Toxicon* 2013, 69: 75–81.
- 275 11. Oliveira SAM, Magalhães MR, Salazar VCR, Valadares MC, Cunha LC:
276 Identification of crotamine in the venom of *Crotalus durissus collilineatus* by
277 three different methods. *Toxicon* 2015, 95:46-51.
278 doi.org/10.1016/j.toxicon.2014.12.015
- 279 12. Motta YP, Sakate M, Nogueira RMB, Floriano RS, Laposy CB, Sanches OC,
280 Camplesi AC. Intoxicação experimental por veneno da serpente *Crotalus*
281 *durissus terrificus* em ratos Wistar: avaliações clínica, laboratorial e
282 histopatológica e tratamento com soro antiofídico e *Mikania glomerata*. *Rev.*
283 *Bras. Toxicol.* 2009, 22:218-218, 2009.
- 284 13. WHO: Progress in the characterization of venoms and standardization of
285 antivenoms. *WHO Offset Publication* 1981, 58: 1–44.
- 286 14. Mise YF, Lira-da-Silva R, Carvalho FM. Time of treatment and severity of
287 snake envenoming in Brazil. *Rev. Panam. Salud Publica.* 2018, 42:1-6.
288 doi.org/10.26633/RPSP.2018.52
- 289 15. CFMV: Guia Brasileiro de Boas Práticas para a Eutanásia em Animais:
290 Conceitos e procedimentos recomendados. Brasília DF: CFMV, 2013 62p.

- 291 16. Gibson-corley KN, Olivier AK, Meyerholz DK: Principles for valid
292 histopathologic scoring in research. *Vet Pathol* 2013, 50: 1–22.
- 293 17. Mann, PC, Vahle J, Keenan CM, Baker JF, Bradley AE, Goodman DG,
294 Harada T, Herbert R, Kaufmann W, Kellner R, Nolte T, Rittinghausen S,
295 Tanaka T: International Harmonization of Toxicologic Pathology
296 Nomenclature: An Overview and Review of Basic Principles. *Toxicol Pathol*
297 2012, 40: 7–13.
- 298 18. Gerez JR, Pinton P, Callu P, Grosjean F, Oswald IP, Bracarense APFL:
299 Deoxynivalenol alone or in combination with nivalenol and zearalenone induce
300 systemic histological changes in pigs. *Exp Toxicol Pathol* 2015, 65:89-98
- 301 19. R Core Team, 2017. R: A language and environment for statistical computing.
302 Vienna, Austria. URL <https://www.R-project.org/>.
- 303 20. Sitprija V, Sitprija: Renal effects and injury induced by animal toxins. *Toxicol*
304 2012, 60: 943–953.
- 305 21. Monteiro HSA, Da Silva IMSC, Martins AMC, Fonteles MC: Actions of *Crotalus*
306 *durissus terrificus* venom and crotoxin on the isolated rat kidney. *Braz J Med*
307 *Biol Res* 2001, 34:1347–1352.
- 308 22. Batista da Cunha D, Silvestrini AVP, Silva ACG, Estevam MPD, Pollettini FL,
309 Navarro JO, Alves AA, Beretta ALRZ, Bizzacchi JMA, Pereira LC, Mazzi MV:
310 Mechanistic insights into functional characteristics of native crotoxin.
311 *Toxicol* 2018, 146: 1–12.
- 312 23. Teixeira TL, Silva VAO, Cunha DB, Pollettini FL, Thomaz CD, Pianca AA,
313 Zambom FL, Mazzi DPSL, Reis RM, Mazzi MV: Isolation, characterization and
314 screening of the in vitro cytotoxic activity of a novel L-amino acid oxidase
315 (LAAOcdt) from *Crotalus durissus terrificus* venom on human cancer cell lines.

- 316 Toxicon 2016, 119:203–217.
- 317 24. Gonçalves R, Vargas LS, Lara MVS, Güllich A, Mandredini V, Ponce-Soto L,
318 Marangoni S, Dal Belo CA, Mello-Carpes PB: Intrahippocampal infusion of
319 crotoamine isolated from *Crotalus durissus terrificus* alters plasma and brain
320 biochemical parameters. *Int J Environ Res Public Health* 2014, 11:11438–
321 11449.
- 322 25. Oliveira SAM, Magalhães MR, Oliveira LP, Cunha LC: Identification of
323 antinociceptive fraction of snake venom from *Crotalus durissus collilineatus*
324 crotoamine-negative and its acute toxicity evaluation. *Toxicon* 2016, 122:145–
325 151.
- 326 26. Torrent RMR, Bongiovanni B, Leiva LC, Duffard AME, Rodríguez JP, Pérez
327 OCA, Duffard R: Neurotoxicological effects of thrombin-like enzyme isolated
328 from *Crotalus durissus terrificus* venom (preliminary study) *Toxicon* 2007,
329 50:144-152
- 330 27. Rádis-Baptista G, Kerkis I: Crotoamine, a small basic polypeptide myotoxin
331 from rattlesnake venom with cell-penetrating properties. *Curr Pharm Des*
332 2011, 17:4351–4361.
- 333 28. Yan CH, Liang ZQ, Gu ZL, Yang YP, Reid P, Qin ZH: Contributions of
334 autophagic and apoptotic mechanisms to CrTX-induced death of K562 cells.
335 *Toxicon* 2006, 47:521–530.
- 336 29. Oliveira-Neto J, Silveira JAM, Serra DS, Viana DA, Borjes-Nojosa DM,
337 Sampaio CMS, Monteiro HSA, Cavalcante FSA, Evangelista JSAM:
338 Pulmonary mechanic and lung histology induced by *Crotalus durissus*
339 cascavella snake venom. *Toxicon* 2017, 137:144-149.
- 340 30. Silva EO, Bracarense APFL, Oswald IP: Mycotoxins and oxidative stress:

- 341 where are we? *World Mycotoxin J* 2018, 11:1–22.
- 342 31. Amora DN, Sousa TM, Martins AMC, Barbosa PSF, Magalhães MR, Toyama
343 MH, Fonteles MC, Menezes DB, Monteiro HSA: Effects of *Crotalus durissus*
344 *collilineatus* venom in the isolated rat Kidney. *Toxicon* 2006, 47:260-264.
- 345 32. Rangel-Santos A, Lima C, Lopes-Ferreira M. Cardoso DF: Immunosuppressive
346 role of principal toxin (crotoxin) of *Crotalus durissus terrificus* venom. *Toxicon*
347 2004, 44:609-616.

ARTIGO 2

1 **Acute testicular toxicity of *Crotalus durissus terrificus* and *Crotalus durissus***
2 ***collilineatus* venom in Wistar rats: A histological comparative study**

3

4 Paulo Felipe Izique Goiozo¹, Liliane Giroto Pereira¹, Elisângela Olegário da Silva²,
5 Elaine Carrion de Fares², André Carrion de Fares Pinto³, Flávia Lima de Godoy³,
6 Adriana Falco de Brito¹ & Rosa Maria Barilli Nogueira¹

7 ¹ Postgraduate Program in Animal Physiopathology and Health – Universidade do
8 Oeste Paulista – Presidente Prudente – São Paulo State - Brazil.

9 ² Veterinary Medicine Course, Universidade do Oeste Paulista - Presidente
10 Prudente, São Paulo State, Brazil.

11 ³ Medicine School, Universidade do Oeste Paulista - Presidente Prudente, São Paulo
12 State, Brazil.

13 * Corresponding author: Postgraduate Program in Animal Physiopathology and
14 Health – Universidade do Oeste Paulista. Rodovia Raposo Tavares, Km 572 – Bairro
15 Limoeiro - Presidente Prudente – São Paulo State – Brazil – Zip Code: 19.067-175.

16

17 E-mail addresses: goiozopfi@gmail.com (P.F.I. Goiozo), liliane135@hotmail.com (L.G.
18 Pereira), elivet02@gmail.com (E.O. Silva), elainecarrionfares@gmail.com (E.C. Fares),
19 andrecf92734@gmail.com (A.C.F. Pinto), flaagodoy@outlook.com (F.L. Godoy),
20 adrianabrito@unoeste.br (A.F. Brito) and rosa@unoste.br (R.M.B. Nogueira).

21

22

23

24

25

26 **Acute testicular toxicity of *Crotalus durissus terrificus* and *Crotalus durissus***
27 ***collilineatus* venom in Wistar rats: A histological comparative study**

28 **ABSTRACT:**

29 The species *Crotalus durissus* is responsible for the highest number of deaths due to
30 ophidian accidents. Although widely researched, there are no studies on the effects
31 of crotalic venom on the tissue morphology of the male reproductive system. *Crotalus*
32 *durissus terrificus* and *Crotalus durissus collilineatus* crotalic venom (1.0 mg / kg)
33 resulted in significant tissue damage ($p < 0.05$), mainly cytoplasmic vacuolization,
34 basement membrane changes and spermatogonia necrosis. In conclusion, our
35 results show that spermatogenesis is compromised by tissue damage caused by
36 crotalic poisoning.

37 **Keywords:** Rattlesnakes; lesional score, spermatogenesis.

38

39 The species *Crotalus durissus* is the only one of the genus in South America, being
40 found from Mexico to the North of Argentina. In Brazil, seven sub-species are found;
41 *Crotalus durissus terrificus*, *Crotalus durissus collilineatus*, *Crotalus durissus*
42 *cascade*, *Crotalus durissus ruruima*, *Crotalus durissus marajoensis*, *Crotalus*
43 *durissus dryinus* and *Crotalus durissus trigonicus* (Uetz, 2006), which inhabit dry,
44 sandy, rocky and rarely coastal areas (Houos and Almeida-Santos, 2016). The
45 venom is a complex mixture of biologically active proteins, enzymes, toxins, and
46 polypeptides that exhibits variation in toxic activity and composition both among
47 subspecies and among individuals of the same subspecies due to variations in diet,
48 habitat and age (Boldrini-França et al., 2010; Dos Santos, 2014; França et al., 2009;
49 Lourenço et al., 2013; Oliveira et al., 2018). Studies show that crotalic venom has
50 neurotoxic, coagulant, myotoxic, nephrotoxic, and hepatotoxic actions (Albuquerque

51 et al., 2013; Fernandes, 2008; França et al., 2009), in animals and humans, however,
52 the deleterious effects on the tissue morphology of the gonads are unknown.
53 Additionally, epidemiological data and governmental statistics indicate that crotalic
54 accidents are responsible for the highest number of deaths in humans and animals
55 (Bastos et al., 2005; Brasil, 2015; Estrada et al., 2014). Due to the complexity and
56 variation of the composition of the crotalic venom, the objective of the present study
57 was to evaluate the effects on tissue in the testes of rats, comparing two subspecies
58 of *Crotalus durissus*.

59 Sixty male rats ninety days old, of the Wistar lineage were used. The animals were
60 kept in an environment with a controlled temperature (22 ± 2 C°) and light / dark
61 cycle of 12 hours. All protocols and behaviors involving the animals of the present
62 study were approved by the Ethics Committee on the Use of Animals under protocol
63 number 3220 (UNOESTE-Brazil).

64 Lyophilized samples of venoms of *Crotalus durissus terrificus* and *Crotalus durissus*
65 *collilineatus* were kept frozen at -20° C until the moment of use.

66 The animals were randomly assigned to three treatments (n = 20): Control Group
67 (CG) inoculated with 0.9% saline solution intramuscularly; *Crotalus durissus terrificus*
68 (Cdt) inoculated with 1.0 mg / kg of venom intramuscularly and *Crotalus durissus*
69 *collilineatus* (Cdc) inoculated with 1.0 mg / kg of venom (Motta et al. 2009). Six hours
70 after inoculation, according clinical previous studies (Mise et al. 2018), the animals
71 were euthanized by inhalation of anesthesia with isoflurane and subsequent
72 exsanguination.

73 The testes were collected and fixed in 10% buffered formalin solution for 48 hours.

74 The tissue samples were embedded in paraffin and the blocks were cut in a semi-


75 automated microtome than 3 μm sections were stained with Hematoxylin and Eosin
76 (HE) and Periodic Acid Schiff (PAS).

77 For histopathological evaluation, a testicular histological score was used. (Gibson-
78 corley et al., 2013; Mann et al., 2012). The testicular lesion score was obtained by
79 multiplying the severity factor by the extent of the lesion. The organ score was then
80 obtained by the sum of each lesion score. The severity factor (degree of severity)
81 was assessed as: 1-mild lesions, 2-moderate lesions and 3-severe lesions. The
82 extent of each lesion (intensity or observed frequency) was evaluated and scored as
83 0-no lesion, 1-low extent (25% of the tissue affected), 2-intermediate extent (50% of
84 the tissue affected) and 3- large extent (75% or more of the tissue affected). Vascular
85 congestion (Severity factor = 1), interstitial edema (Severity factor = 1), basal
86 membrane integrity (Severity factor = 2), sperm cells cytoplasmic vacuolization
87 (Severity factor = 2) and sperm cells necrosis (Severity factor = 3) were considered
88 to determine the maximum lesional score.

89 The data obtained were evaluated for normality and homogeneity by the Shapiro-
90 Wilk and Bartlett tests, respectively. Subsequently, a non-parametric analysis of
91 variance (ANOVA) was performed using the Kruskal-Wallis test with Dunn's test to
92 determine the differences between the groups, with a significance level of 5% (p
93 <0.05) (Dinno, 2017). All analyzes were performed with Software R Studio (Version
94 3.4.0) (R Core Team, 2017).

95 The testes (right and left) of the control, Cdc, and Cdt rats were collected and
96 submitted to histopathological evaluation. Animals of the control group presented
97 only mild peripheral interstitial edema and mild vascular congestion. Higher lesional
98 score were observed in the Cdt, and Cdc when compared with the control group (Fig.
99 1).

100




101

102 **Figure – 1:** Median of the lesion score-endpoint of the testis of rats inoculated with
 103 crotoalic venom. The line in the center denotes the median, the upper and lower edges
 104 indicate the interquartile deviation and the outside lines indicate the maximum and
 105 minimum values. Equal letters (a) do not differ from each other ($P > 0.05$).

106

107 In groups of poisoned animals, cytoplasmic vacuolization was observed in more than
 108 75% of the tubules. The integrity of the basement membrane (Fig. 2) was affected in
 109 approximately 50% of the tubules, as well as the frequency of spermatogonia
 110 necrosis. Peripheral interstitial edema and discrete vascular congestion were also
 111 observed in the Cdt and Cdc.



112

113 **Figure – 2:** A: Seminiferous tubules, in **A** (Cdc) and **B** (Cdt) It is observed a basal
 114 membrane with irregular contour and weakly stained (arrow) (PAS, 400x). **C** (CG)

115 Seminiferous tubules with preserved and strongly stained basement membrane
116 (PAS, 400x).

117

118 Our results confirm those of a previous study (Fernandes et al., 2018) that
119 demonstrated that the venom of *Crotalus durissus* sp. affects spermatogenesis
120 resulting in increased morphological abnormalities and decreased sperm
121 concentration.

122 The effects of crotalic venom have been widely studied in recent decades and
123 significant advances have been reported in both toxic tissue action (Dos-santos,
124 2014) and the pharmaceutical use of substances that make up the venom such as
125 crotamine (Batista da Cunha et al., 2018). The present study, in spite of all the
126 investigations involving the actions and uses of rattlesnake venom of the species
127 *Crotalus durissus*, is the first to describe the tissue damages caused in the testicles.

128 Tissue lesions in the testicles by toxic agents may act by breaking the blood-
129 testicular barrier, inducing exfoliation of germ cells (Gao et al., 2016) or degenerative
130 and necrotic processes of spermatogonia (Tabassum et al., 2017). Among the
131 components of crotalic venom, crotoxin has edematogenic, inflammatory and
132 necrotizing action and phospholipase (PLA₂) presents important cytotoxic potential
133 (Silva et al., 2012). In our study, the control group (CG) exhibited normal
134 spermatogenesis, with an intact basement membrane and the presence of all cells of
135 the spermatogenic lineage, as well as spermatozooids in the tubular lumen. In the
136 poisoned groups (Gdc) and (Gct), degenerative and necrotic processes were
137 observed at the same intensity ($p > 0.05$), indicating the effects of the crude venom on
138 the testicular tissue.

139 In the testicles, toxic agents penetrate the seminiferous tubules through a selective
140 influx from the apical complex, acting rapidly on the cytoskeletal actin (Su et al.,

141 2011). As observed in our results, the dose used and short time period (1mg/Kg for
142 six hours) demonstrated that crotalic venom demonstrates the properties of breaking
143 the hematopoietic barrier and affecting spermatogenesis.

144 The mechanisms involved in the degenerative and necrotic processes of
145 spermatogonia may be associated with the penetrating capacity of crotamine, leading
146 to damage to mitochondrial membranes (Batista da Cunha et al., 2018). In addition,
147 exposure time and venom concentration are directly related to clinical severity (Mise
148 et al., 2018), and may induce apoptosis or necrosis through the release of
149 cytochrome C, oxidative stress and disruption of ATP synthesis (da Silva et al., 2018;
150 Yan et al., 2006).

151 Ischemic injuries result in severe testicular lesions leading to the detachment of
152 Sertoli cells from the basal membrane and degeneration of spermatogonia (Yazama
153 et al., 2015). In addition, crotamine is a fraction of the crotalic venom that promotes
154 platelet aggregation (Batista da Cunha et al., 2018), and in this context, vascular
155 events should be considered as adjuvants in testicular injury caused by crotalic
156 poisoning, since this polypeptide is present in the venom of *Crotalus durissus*
157 *terrificus* and *Crotalus durissus collilineatus* (Oliveira et al., 2018).

158 This study concludes that exposure to venom of the subspecies *Crotalus durissus*
159 *terrificus* and *Crotalus durissus collilineatus* induced acute testicular toxicity and
160 reduced spermatogenesis, indicating the need to monitor the fertility of humans and
161 animals.

162 **Acknowledgements:** Universidade do Oeste Paulista for financial support (Protocol:
163 3220)

164

165 **REFERENCES**

- 166 Albuquerque, P.L.M.M., Jacinto, C.N., Junior, G.B.S., Lima, J.B., 2013. Review acute
167 kidney injury caused by *Crotalus* and *Bothrops* snake venom: A review of
168 epidemiology, clinical manifestations and treatment. *Rev. Inst. Med. Trop. Sao*
169 *Paulo* 55, 295–301. <https://doi.org/10.1590/S0036-46652013000500001>
- 170 Bastos, E.G. de M., Araújo, A.F.B. de, Silva, H.R. da, 2005. Records of the
171 rattlesnakes *Crotalus durissus terrificus* (Laurenti) (Serpentes, Viperidae) in the
172 State of Rio de Janeiro, Brazil: a possible case of invasion facilitated by
173 deforestation. *Rev. Bras. Zool.* 22, 812–815. [https://doi.org/10.1590/S0101-](https://doi.org/10.1590/S0101-81752005000300047)
174 [81752005000300047](https://doi.org/10.1590/S0101-81752005000300047)
- 175 Batista da Cunha, D., Pupo Silvestrini, A.V., Gomes da Silva, A.C., Maria de Paula
176 Estevam, D., Pollettini, F.L., de Oliveira Navarro, J., Alves, A.A., Remédio Zeni
177 Beretta, A.L., Annichino Bizzacchi, J.M., Pereira, L.C., Mazzi, M.V., 2018.
178 Mechanistic insights into functional characteristics of native crotamine. *Toxicon*
179 146, 1–12. <https://doi.org/10.1016/j.toxicon.2018.03.007>
- 180 Boldrini-França, J., Corrêa-Netto, C., Silva, M.M.S., Rodrigues, R.S., De La Torre, P.,
181 Pérez, A., Soares, A.M., Zingali, R.B., Nogueira, R.A., Rodrigues, V.M., Sanz, L.,
182 Calvete, J.J., 2010. Snake venomomics and antivenomics of *Crotalus durissus*
183 subspecies from Brazil: Assessment of geographic variation and its implication
184 on snakebite management. *J. Proteomics* 73, 1758–1776.
185 <https://doi.org/10.1016/j.jprot.2010.06.001>
- 186 Brasil, 2015. Óbitos por Acidentes por Serpentes. Brasil, Grandes Regiões e
187 Unidades Federativas. 2000 a 2013. Ministério da Saúde.
188 [http://portalarquivos2.saude.gov.br/images/pdf/2014/julho/10/Tabela-08---](http://portalarquivos2.saude.gov.br/images/pdf/2014/julho/10/Tabela-08---OBITOS---serpente---2000-a-2013---21-05-2014.pdf)
189 [OBITOS---serpente---2000-a-2013---21-05-2014.pdf](http://portalarquivos2.saude.gov.br/images/pdf/2014/julho/10/Tabela-08---OBITOS---serpente---2000-a-2013---21-05-2014.pdf), Accessed date: 19 July
190 2018:

- 191 Dinno, A., 2017. dunn.test: Dunn's Test of Multiple Comparisons Using Rank Sums.
192 R package version 1.3.4. <https://CRAN.R-project.org/package=dunn.test>
- 193 Dos-santos, M.C., 2014. Crotoxina e crotoxina-simile isoladas de venenos de
194 subespécies de *Crotalus durissus* e suas múltiplas atividades. *Amaz. Sci.* 3,
195 102–115.
- 196 Estrada, J.S., Quintana, C., Castillo, L., Vargas, J., 2014. Accidente ofídico en
197 animales de pastoreo : acercamiento epidemiológico , clínico y de manejo. *Acta*
198 *Toxicol.Argentina* 18, 10–20.
- 199 Fernandes, T.A., Aguiar, C.N., Daher, E.F., 2008. Envenenamento Crotálico:
200 epidemiologia, insuficiência renal aguda e outras manifestações clínicas. *Rev.*
201 *Eletrônica Pesqui. Médica* 2, 01-10.
- 202 Fernandes, F.H., Bustos-Obregon, E., Matias, R., Dourado, D.M., 2018. *Crotalus*
203 *durissus* sp. rattlesnake venom induces toxic injury in mouse sperm. *Toxicon*
204 153, 17–18. <https://doi.org/10.1016/j.toxicon.2018.08.006>
- 205 França, R., Vieira, R., Ferrari, E., Souza, R., Osorio, R., Prianti-Jr, A., Hyslop, S.,
206 Zamuner, S., Cogo, J., Ribeiro, W., 2009. Acute hepatotoxicity of *Crotalus*
207 *durissus terrificus* (South American rattlesnake) venom in rats. *J. Venom. Anim.*
208 *Toxins Incl. Trop. Dis.* 15, 61–78. [https://doi.org/10.1590/S1678-](https://doi.org/10.1590/S1678-91992009000100007)
209 [91992009000100007](https://doi.org/10.1590/S1678-91992009000100007)
- 210 Gao, Y., Mruk, D.D., Cheng, Y., 2016. Sertoli cells are the target of environmental
211 toxicants in the testis – a mechanistic and therapeutic insight 19, 1073–1090.
212 <https://doi.org/10.1517/14728222.2015.1039513.Sertoli>
- 213 Gibson-corley, K.N., Olivier, A.K., Meyerholz, D.K., 2013. Principles for valid
214 histopathologic scoring in research. *Vet. Pathol.* 50, 1–22.
215 <https://doi.org/10.1177/0300985813485099.Principles>

- 216 Houos, M.A., Almeida-Santos, S.M., 2016. The South-American rattlesnake *Crotalus*
217 *durissus*:feeding ecology in the central region in Brazil. *Biota Neotrop.* 16, 5.
218 <https://doi.org/10.1590/1676-0611-BN-2014-0027>
- 219 Lourenço, A., Fernanda, C., Creste, Z., Curtolo, L., Barros, D., Delazari, L., Pimenta,
220 D.C., Barraviera, B., Seabra, R., Jr, F., 2013. Toxicon Individual venom pro fi ling
221 of *Crotalus durissus terri fi cus* specimens from a geographically limited region :
222 Crotamine assessment and captivity evaluation on the biological activities.
223 *Toxicon* 69, 75–81. <https://doi.org/10.1016/j.toxicon.2013.01.006>
- 224 Mann, P.C., Vahle, J., Keenan, C.M., Baker, J.F., Bradley, A.E., Goodman, D.G.,
225 Harada, T., Herbert, R., Kaufmann, W., Kellner, R., Nolte, T., Rittinghausen, S.,
226 Tanaka, T., 2012. International Harmonization of Toxicologic Pathology
227 Nomenclature: An Overview and Review of Basic Principles. *Toxicol. Pathol.* 40,
228 7S–13S. <https://doi.org/10.1177/0192623312438738>
- 229 Mise, Y., Lira-da-Silva, R., Carvalho, F., 2018. Time to treatment and severity of
230 snake envenoming in Brazil. *Rev. Panam. Salud Pública* 42, 1–6.
231 <https://doi.org/10.26633/RPSP.2018.52>
- 232 Motta YP. Sakate M, Nogueira RMB, Floriano RS, Laposy CB, Sanches OC,
233 Camplesi AC. Intoxicação experimental por veneno da serpente *Crotalus*
234 *durissus terrificus* em ratos Wistar: avaliações clínica, laboratorial e
235 histopatológica e tratamento com soro antiofídico e *Mikania glomerata*. *Rev.*
236 *Bras. Toxicol.* 2009, 22:218-218.
- 237 Oliveira, I.S. de, Cardoso, I.A., Bordon, K. de C.F., Carone, S.E.I., Boldrini-França,
238 J., Pucca, M.B., Zoccal, K.F., Faccioli, L.H., Sampaio, S.V., Rosa, J.C., Arantes,
239 E.C., 2018. Global proteomic and functional analysis of *Crotalus durissus*
240 *collilineatus* individual venom variation and its impact on envenoming. *J.*

- 241 Proteomics 1–13. <https://doi.org/10.1016/j.jprot.2018.02.020>
- 242 R Core Team, 2017. R: A language and environment for statistical computing.
243 Vienna, Austria. URL <https://www.R-project.org/>.
- 244 Silva, E.O., Bracarense, A.P.F.L., Oswald, I.P., 2018. Mycotoxins and oxidative
245 stress: where are we? *World Mycotoxin J.* 11, 1–22.
246 <https://doi.org/10.3920/WMJ2017.2267>
- 247 Silva, T.F., Santos, G.T., Mendonça, F.S., Soares, A.M., Neves, L.M.G., 2012.
248 Avaliação histológica dos efeitos da crotoxina de – *Crotalus durissus terrificus*
249 na pele do dorso de ratos Wistar 8, 1–9.
- 250 Su, L., Mruk, D.D., Cheng, C.Y., 2011. Drug transporters, the blood–testis barrier,
251 and spermatogenesis. *J. Endocrinol.* 91, 165–171.
252 <https://doi.org/10.1016/j.chemosphere.2012.12.037>.Reactivity
- 253 Tabassum, H., Parvez, S., Raisuddin, S., 2017. Melatonin abrogates nonylphenol-
254 induced testicular dysfunction in Wistar rats. *Andrologia* 49, 1–9.
255 <https://doi.org/10.1111/and.12648>
- 256 Uetz, P., 2006. The Reptile Database. <http://www.reptile-database.org>, Accessed
257 date: 17 July 2018.
- 258 Yan, C.H., Liang, Z.Q., Gu, Z.L., Yang, Y.P., Reid, P., Qin, Z.H., 2006. Contributions
259 of autophagic and apoptotic mechanisms to CrTX-induced death of K562 cells.
260 *Toxicol.* 47, 521–530. <https://doi.org/10.1016/j.toxicol.2006.01.010>
- 261 Yazama, F., Sato, H., Sonoda, T., 2015. Malfunction of spermatogenesis in
262 experimental ischemic mice. *J. Reprod. Dev.* 61, 399–406.
263 <https://doi.org/10.1262/jrd.2015-028>
- 264

ANEXO 1 - PARECER FINAL DA COMISSÃO DE ÉTICA E USO DE ANIMAIS (CEUA/UNOESTE)

12/13/2018

Certificado

UNOESTE - Universidade do Oeste Paulista

PRÓ-REITORIA DE PESQUISA E PÓS-GRADUAÇÃO

PPG - Programa de Pesquisa de Pós-Graduação
PEIC - Programa Especial de Iniciação Científica

Parecer Final

Declaramos para os devidos fins que o Projeto de Pesquisa intitulado "ESTUDO COMPARATIVO DOS EFEITOS DO VENENO BRUTO DE SERPENTES CROTALUS DURISSUS TERRIFICUS (LAURENTI, 1768) E CROTALUS DURISSUS COLLILINEATUS (AMARAL, 1926) EM LESÕES SISTÊMICAS OCACIONADAS PELA INTOXICAÇÃO EXPERIMENTAL EM RATOS WISTAR", cadastrado na Coordenadoria de Pesquisa, Desenvolvimento e Inovação (CPDI) sob o número nº 3220 e tendo como participante(s) ROSA MARIA BARILLI NOGUEIRA (responsável), KARINE MARIELE GUIMARAES DE CASTRO (discente), LILLANE GIROTO PEREIRA (discente), PAULO FELIPE IZIQUE GOIOZO (discente), foi avaliado e APROVADO pelo COMITÊ ASSESSOR DE PESQUISA INSTITUCIONAL (CAPI) e COMISSÃO DE ÉTICA USO DE ANIMAIS (CEUA) da Universidade do Oeste Paulista - UNOESTE de Presidente Prudente/SP.

Este Projeto de Pesquisa, que envolve a produção, manutenção e/ou utilização de animais pertencentes ao filo Chordata, subfilo Vertebrata (exceto o homem), para fins de pesquisa científica, encontra-se de acordo com os preceitos da Lei nº 11.794, de 8 de Outubro de 2008, do Decreto nº 6.899, de 15 de Julho de 2009, e com as normas editadas pelo Conselho Nacional de Controle da Experimentação Animal (CONCEA), tendo sido APROVADO em reunião realizada em 08/06/2016.

Vigência do projeto: 05/2016 a 09/2018.

Espécie/Linhagem	Nº de Animais	Peso	Idade	Sexo	Origem
Ratos Wistar	84	350 gramas	180 dias	M	Biotério

Presidente Prudente, 17 de Junho de 2016.



Prof. Doutor Rodrigo Garcia Jr.
Coordenador Científico da CPDI



Prof. Ms. Adriana Falco de Brito
Coordenadora da CEUA - UNOESTE

valide este documento em www.unoeste.br/ppg informando o código de segurança e150c9e8ec0f64737d54ed1b2367952c

<http://www.unoeste.br/SQP/certificados/ver.asp?h=e150c9e8ec0f64737d54ed1b2367952c>

1/1

ANEXO 2 - TERMO DE DOAÇÃO DOS VENENOS UTILIZADOS NO ESTUDO



Coletor Herpetológica do Centro de Estudos e
Pesquisas Biológicas – PUC Goiás

Escola de Ciências Agrárias e Biológicas, ECAB
Av. Engler, s/n, Goiânia, GO, Brasil
CEP: 74885-460
Fone: (62) 2946-1748



Para: Dr. Nelson Jorge da Silva Jr. (To)	Coletor de Répteis (Heterôto) (Collector of)
Mestrado em Ciências Ambientais e Saúde Pontifícia Universidade Católica de Goiás	Guia de Remessa nº: 01/2018 (Shipping ticket #)
	Data: 04/04/2018 (Date)
	Período: não se aplica (Leap period)

Este material está sendo enviado como (This material is being sent as):

- | | |
|---|--|
| <input type="checkbox"/> Empréstimo (loan) | <input type="checkbox"/> Desenvolvimento (Return) |
| <input type="checkbox"/> Préstimo (exchange) | <input type="checkbox"/> Identificação cruzada (crossed) |
| <input checked="" type="checkbox"/> Doação (Gift) | <input type="checkbox"/> Outros (Other): |

Discriminação:
(Discrimination)

Alíquotas de veneno de *Crotalus durissus* (30mg, classe 1 = jovem; 30mg, classe 2 = subadulto);
30mg, classe 3 = adulto) para uso no projeto "Análise clínica e laboratorial dos efeitos do
veneno bruto da serpente *Crotalus durissus collilanceus* (Amorim, 1976) em ratos Wistar".

Materiais recebidos em boas condições (Material received in good order)	Autorizado: (Authorized)
Assinatura: (Signature)	Dr. Nelson Jorge da Silva Jr. Coordenador do CEPB
Data: (Date)	Responsável pelo transporte: (Responsible for transport)
Favor assinar e devolver a cópia (Please sign and return the copy)	Data: 04/04/2018 (Date)

ANEXO 3 - NORMAS DE PUBLICAÇÃO DOS PERIÓDICOS

Acta Veterinaria

INSTRUCTIONS FOR AUTHORS

Submission of Manuscript

The manuscript should be uploaded as a single file Microsoft Word document (.doc format). Figures, illustrations and tables should be uploaded as separate files. An accompanying letter, signed by all authors must provide assurance that the paper is not under consideration by another journal or publication source. Together with the manuscript authors are required to submit a scanned copy of the signed original, *Competing interests*, *Authors contribution* and *License to Publish*, which can be downloaded from the Journal homepage. Approval of the ethics committee must be obtained prior to the start of the study and be available upon request.

Review Procedure

The Journal offers a fast online and full color printed publication for all articles which have not been published or considered for publication elsewhere, and peer-review is managed electronically. The Editorial Board reserves the right to reject a manuscript that is not within the scope of the journal and does not meet the standards and requirements for publication. The Editor-in-Chief nominates peer referees (at least two) upon recommendation of the Editorial Board members. The Journal list of reviewers is continually updating and expanding with new reviewers according their active participation in the evaluation process. The submitted manuscripts are sent to the referees together with the instructions for reviewers accompanied with *Letter referee form*. Acceptance of the manuscript is decided, based on the reviews and recommended decision of the referees. A referee's decision is made as "Accept", "Accept after revision" and "Reject". If there is marked discrepancy in the decisions between the referees the Editor-in-Chief may send the manuscript to another referee for additional comments and recommended decision. Name and individual decisions of the referees are not transmitted to the author. The peer review process may in general take four weeks after submission of the manuscript. Reviewers are asked to note whether they think duplication or plagiarism has occurred. Corresponding author must indicate clearly what alterations have been made in response to the referee comments point by point. Corrections should be returned within 3 days. Accepted articles are published on www.actaveterinaria.rs and then selected for a subsequent print issue.

Article-processing charges

Open access publishing (www.degruyter.com/view/j/acve) is not without costs. Acta Veterinaria therefore levies an article-processing charge of €120 (VAT included) for each article accepted for publication. The Acta Veterinaria is freely available without charge to the user or institution. Acta Veterinaria is an Open Access Journal. All articles can be downloaded free of charge and used in accordance with the Creative Commons Attribution 4.0 International (CC BY 4.0).

Preparation of Manuscript

The complete manuscript should be prepared according to instructions given in this section.

General guidelines of the Journal's style and language: the manuscript must be written in clear and concise English language and should be checked by a native-English speaker or certified English instructor with a good understanding of scientific terminology.

Type the manuscript double-spaced, using 12 font size and 3,0 cm margins. The journal requires line numbering in submitted manuscripts. Number the pages consecutively with the title page being page 1. Original research articles, case reports and methodology articles should usually occupy no more than eight printed pages. Text headings should be typed in capitals and subheadings in *italics* with an only initial capital letter. The text may contain a few short subheadings.

Original research articles should report on original primary research. Original research articles should be subdivided in: Title page, Summary and Keywords, Introduction, Material and Methods, Results, Discussion, Acknowledgements, References, Tables / Figures / Illustrations (with Legends).

Methodology articles should present a new method, test or procedure. The method described may either be completely new, or may offer an improved version of an existing method. The article must describe a clear advantage over what is currently available. The method needs to have been well tested and ideally, but not necessarily, used in a way that proves its value. Methodology articles should be subdivided into Title page, Summary and Key words, Introduction, Methods - Results and Discussion, Conclusions, Acknowledgements, References, Tables, Figures, Illustrations (with Legends). The **Accession Numbers** of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets and include the corresponding database name.

Case reports and **Short communication** submitted to *Acta Veterinaria* must have educational value or highlight the need for a change in clinical practice or diagnostic/prognostic approaches. *Acta Veterinaria* will not consider Case reports describing preventive or therapeutic interventions, as these generally require stronger evidence. *Acta Veterinaria* welcomes well-described reports of cases that include the following: unreported or unusual side effects or adverse interactions involving medication; unexpected or unusual presentations of a disease; an unexpected association between diseases or symptoms; an unexpected event in the course of observing or treating an animal and findings that shed new light on the possible pathogenesis of a disease or an adverse effect. Authors are encouraged to describe how the Case report is rare or unusual as well as its educational and/or scientific merits in the covering letter that will accompany the submission of the manuscript. Case reports should be subdivided into Title page, Summary and Key words, Introduction, Case presentation, Acknowledgements, References, Tables/Figures/Illustrations (with Legends).

In Short communication, Results and Discussion section is the interpretation of the results and their relation to the existing knowledge. The contribution to Veterinary medicine must be clearly stated.

Title Page

The Title page should include:

1. Short and informative title in capital letters.
2. Names of all authors (with only initial capital letters) followed by their affiliations: department, institution, city without postcode, country. If there is more than one institution involved, authors names should be linked to the appropriate institutions by inserting numbers in superscript after relevant names.
3. Full name, e-mail, fax phone number and mailing address of the corresponding author should be typed at the bottom.

Summary and Key Words

Summary should be short and clear, with no more than 250 words. Reference citations must not appear in the summary and abbreviations should be avoided. The summary should provide a basic-level introduction to the field; a brief account of the background and principle of the work; a statement of the main conclusions; and 2-3 sentences that place the main findings into a general context. All manuscripts should be followed by a Summary in Serbian. This will be provided by publisher for authors from outside Serbia countries.

Below the end of English and Serbian Summary four to six Key words in alphabetical order should be provided, using the entries from Index Medicus for indexing purposes.

Introduction

The essence of the problem and the purpose of the study should be pointed at the introduction. References discussed in the manuscript should be cited.

Materials and Methods

Identify the methods and procedures in sufficient details to allow other workers to reproduce the results. If methods are widely known, they should not be described, but only references indicated. Give references to established methods including statistical methods. Specify any general computer program used. Identify all drugs and chemicals used with generic names, doses and route of administration. Provide manufacturer and product number where applicable.

Informed consent: Journal Acta Veterinaria Beograd ask authors not only to confirm that ethical and legal approval was obtained prior to the start of the study, and state the name of the body giving the approval, but also authors are asked to confirm that animals did not suffer unnecessarily at any stage of an investigation and authors should provide Statement of Informed Consent. All articles related to companion animals should include written consent as mandatory part of *Consent section* and authors should provide given consent from the owner. The protection of privacy is legal right that must not be breached without individual informed consent. In case where the identification of personal information is necessary for scientific reasons, authors should obtain written permission for the client-owned animals.

The following (or similar) statement should be included in the end of Material and methods section: *Informed consent: Informed consent has been obtained for client-owned animals included in this study.*

Ethics

Experimental research on vertebrates or any regulated invertebrates must comply with institutional (e.g. Institutional Animal Care and Use Guidelines), national (e.g. Law for animal welfare protection) and international guidelines (e.g. Directive 2010/63/EU in Europe). It is the responsibility of the authors to obtain approval of appropriate regulatory group and report this approval in their manuscript in the first paragraph of the section Materials and methods including the name of the regulatory group, reference number and date of the approval.

The research using animal subjects should be conducted according to the Principles of Laboratory Animal Care and similar documents (e.g. <http://grants.nih.gov/grants/olaw/olaw.htm>).

The design of studies involving client-owned animals should include documentation of informed client consent.

The Editor may request further information about care and use of animals including evidence of regulatory approval, client consent and compliance with local regulations.

The Editor reserves the right to decline to publish manuscripts if he has concerns about the welfare or treatment of animals used in the study.

Examples: *Ethical approval: The research related to animals use has been complied with all the relevant national regulations and institutional policies for the care and use of animals (name of regulatory group, number and date).*

If the manuscript does not contain any study that requires animal ethical approval, the following statement should be included in the Material and methods section: *Ethical approval: The conducted research is not related to animals use. No ethical approval was obtained because this study did not involve laboratory animals and only involved non-invasive procedures (e.g. collection of waste tissue after surgery, fecal samples, voided urine etc).*

When reporting experiment on animals indicate whether the national law on the care and use of animals was followed. Approval of the ethics committee must be obtained prior to the start of the study and should be available upon request. When reporting in addition experiments in human subjects, manuscripts must include assurance that the study was performed in conformance with the Declaration of Helsinki ethical guidelines. See the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at <http://www.icmje.org>. Authors are required to submit a scanned copy of the signed original, Statement of human and animal rights.

Results

Results should be presented in logical sequence, using tables and figures without duplication. The data should be precise and expressed according to the International System of Units (**SI**).

Discussion

Results should be discussed and related to other relevant studies. The Conclusions should be linked with the goals of the study, avoiding unqualified statements and conclusions not supported by your data. The new information should be distinguished from the previous finding and relevant hypothesis may be generated.

Acknowledgements

Acknowledgements should be placed at the end of the text indicating financial support or technical assistants. Name of the funding organizations should be written in full.

References

Citations such as *personal communications*, *unpublished data* or *in press* are not accepted. Meeting abstract may be cited only if published in indexed journals. Only essential references should be included in the text by Arabic numerals in square brackets and numbered consecutively in the order in which they are mentioned in the text. Always the same number is indicated in square brackets for the reference which is cited several times in the text. Automatic numbering should be avoided. References are typed on sheets separate from the text and follow the text.

Journal abbreviations follow Index Medicus/MEDLINE. List all authors. Authors are encouraged to use EndNote. Otherwise references must be given in the following format:

Articles

Simpson VR, Davison NJ, Kearns AM, Pichon B, Hudson LO, Koylass M, Blackett T, Butler H, Rasigade JP, Whatmore AM: Association of a lukM-positive clone of *Staphylococcus aureus* with fatal exudative dermatitis in red squirrels (*Sciurus vulgaris*). *Vet Microbiol* 2013, 162:987–991.

Abstracts

Marinkovic D, Aleksic-Kovacevic S, Knezevic M: Verminous arteritis of the cranial mesenteric artery of horses: the role of arterial smooth muscle cells [abstract]. *J Comp Pathol* 2010, 143:351.

Book and Monographs

Munson L, Terio KA, Ryser-Degiorgis MP, Lane EP, Courchamp F: Wild felid diseases: conservation implications and management strategies. In: *Biology and conservation of wild felids*. Oxford, United Kingdom: Oxford University Press; 2010, 237-259.

Link

Neylon C: Open Research Computation: an ordinary journal with extraordinary aims. [http://blogs.openaccesscentral.com/blogs/bmcblog/entry/open_research_computation_an_ordinary]

Figures, illustrations and tables

Images must be at resolution 300dpi (1200 x 900 pixels). Allowable formats – JPG, TIFF. For microphotographs scale bars with appropriate units should be provided. Symbols, arrows or letters used in photographs should contrast with the background.

The **legends** should be included in the main manuscript text file at the end of the document, rather than being a part of the figure file. For each figure, the following information should be provided: Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc.) and detailed legend. Uppercase letters A,B,C, etc. should be used to identify parts of multipart figure.

Each **table** should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.). Tables should also have a title (above the table) that summarizes the whole table; it should be no longer than 15 words. Detailed legends may then follow, but they should be concise. Tables should always be cited in text in consecutive numerical order. Tables should be uploaded in a separate file as a Microsoft Word (.doc) document. Columns and rows of data should be made visibly distinct by ensuring that the borders of each cell display as black lines. Commas should not be used to indicate numerical values. Colour and shading may not be used; parts of the table can be highlighted using symbols or bold text, the meaning of which should be explained in a table legend.

Abbreviations: Abbreviations which are not standard should be defined in the text when first used. Restrict the use of abbreviations to SI (System International) symbols.

Competing interests: A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with other people or organizations. Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.

Author's contributions: In order to give appropriate credit to each author of a paper, the individual contributions of authors to the manuscript should be specified in this section.

An author is generally considered to be someone who has made substantive intellectual contributions to a published study. All contributors who do not meet the criteria for authorship should be listed in an acknowledgements section.

Copyright: It is condition of publication that authors assign *License to Publish* document to Acta Veterinaria.

Journal Address

Acta Veterinaria

Prof. Dr Sanja Aleksic-Kovacevic, Editor-in-Chief
Faculty of Veterinary Medicine, University of Belgrade
Bulevar oslobodjenja 18,
Belgrade, 11000, Serbia - e-mail: acta@vet.bg.ac.rs

Acta Veterinaria

Ass. Prof. Dr Vladimir Kukolj, Technical Editor
Faculty of Veterinary Medicine, University of Belgrade
Bulevar oslobodjenja 18,
Belgrade, 11000, Serbia - E-mail: acta@vet.bg.ac.rs

Please also visit *Acta Veterinaria* homepage at

www.actaveterinaria.rs - e-mail: acta@vet.bg.ac.rs

Journal of Comparative Pathology

Guide for Authors

Scope

The *Journal of Comparative Pathology* exists to publish articles recording research and original scientific findings relevant to the diseases of domesticated and other vertebrate animals. Articles on diseases of man are also appropriate if they present features of special interest when viewed against the general background of vertebrate pathology.

In addition, the Journal may publish Short Papers. These are intended to include reports of small completed investigations, new techniques or case descriptions. They should not have the subdivisions of a full length paper, but should include a brief summary and essential references. They would normally not exceed a word limit of 2000 and should include no more than four supportive figures (as individual images not composites of multiple images) or tables. Such submissions should be clearly marked 'Short Paper'. Single case reports will be accepted only if they make a significant contribution to knowledge.

The Journal publishes Review Articles on topics of broad interest from invited authors with acknowledged expertise in their field. Unsolicited Review Articles will be considered, but authors intending to prepare a review should first contact the Editor-in-Chief to discuss their proposal for a review article.

The Journal will publish 'Mini Reviews' on topical subjects that fall within the overall scope of the Journal. A Mini Review will summarize in succinct fashion the key points related to (for example) the pathogenesis and pathology of a disease process and provide a 'cutting edge' overview of current research and future research directions related to that disease or subject area. Mini Reviews will normally be commissioned by the Editor of the Journal, but unsolicited contributions will be considered and subjected to the normal peer review process.

- A Mini Review will be restricted to a 1,750 to 2,000 word limit (not including summary and references) and key points may be made by the use of bullet points.
- A Mini Review will be supported by no more than 10 key current references. References need not be cited within the text in standard Journal format, but can appear as a list of 'Key References'.
- A Mini Review should be supported by between four to six photographic images (e.g. of gross or microscopical pathology or diagrammatic summaries of key disease mechanisms).
- A Mini Review must have a standard Summary (abstract) with four suggested key words.
- A Mini Review should follow the general Journal format for title, authors and affiliations, reference and citation style, acknowledgments and Conflict of Interest Statement as detailed within the Notes for Contributors.

Page charges

This journal has no page charges.

Ethics in publishing

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

Animal Experimentation

Circumstances relating to animal experimentation must meet the International Guiding Principles for Biomedical Research Involving Animals as issued by the Council for the International Organizations of Medical Sciences. They are obtainable from: Executive Secretary C.I.O.M.S., c/o WHO, Via Appia, CH-1211 Geneva 27, Switzerland, or at the following URL: http://www.cioms.ch/publications/guidelines/1985_texts_of_guidelines.htm.

Such studies must meet Animals in Research: Reporting In Vivo Experiments (ARRIVE) guidelines (https://www.elsevier.com/data/promis_misc/ARRIVE.pdf). Unnecessary suffering in animal experimentation is not acceptable to the Editors of the *Journal of Comparative Pathology*. Authors must indicate the nature of ethical approval for a study in the appropriate section of the Materials and Methods of a manuscript.

Declaration of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](#).

Conditions of Acceptance

The Editorial Board accepts papers on the understanding that they have not been published elsewhere and, if accepted, will not be reprinted in whole or in part without the Board's written approval. The Board reserves the right to reject, on scientific, ethical or other grounds, any manuscript submitted to it. Each person named in the list of authors of a paper must have made a substantial scientific or critical contribution to the work described and have read and approved the version submitted to the Journal.

Papers will be published with the minimum of delay, bearing the dates of receipt and acceptance. The period between receipt of an article and publication depends on the amount of editorial work and correspondence required and the number of articles already awaiting publication. Exceptionally, the Editor may use discretion in determining whether a degree of accelerated publication could be offered.

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no

assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

Article transfer service

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. [More information](#).

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of gold open access articles is determined by the author's choice of [user license](#).

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Funding body agreements and policies

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the gold open access publication fee. Details of [existing agreements](#) are available online.

After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

Open access (OA)

This journal offers authors a choice in publishing their research:

Open Access

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or their research funder

Subscription

- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (<http://www.elsevier.com/access>)
- No open access publication fee

All articles published open access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

Elsevier has established agreements with funding bodies, <http://www.elsevier.com/fundingbodies>. This ensures authors can comply with funding body open access requirements, including specific user licenses, such as CC BY. Some authors may also be reimbursed for associated publication fees. If you need to comply with your funding body policy, you can apply for the CC BY license after your manuscript is accepted for publication.

To provide open access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published open access. Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The gold open access publication fee for this journal is **USD 3000**, excluding taxes. Learn more about Elsevier's pricing policy: <https://www.elsevier.com/openaccesspricing>.

Green open access

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [green open access page](#) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested

during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more.](#)

This journal has an embargo period of 12 months.

Language services

The *Journal of Comparative Pathology* is published in British and not American English. Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop <http://webshop.elsevier.com/languageediting/> or visit our customer support site <http://support.elsevier.com> for more information.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit **your** **article**
Please submit your article via <https://www.eviser.com/profile/api/navigate/YJCPA/>.

Peer review

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

Format of Articles

Articles must be concise and unnecessary duplication of data in text, tables and graphs should be avoided. Allusions to published work must be brief and limited to what is necessary to evaluate the findings in the manuscript. Extensive reviews of the literature will not be permitted, except in Review Articles.

To avoid repetition, if a related article by the same authors, or some of them, is being offered to a different journal, a copy of that article must be provided, in confidence, for comparison.

Before submitting manuscripts authors are recommended to consult recent issues of the Journal to see the form in which the articles appear.

Manuscripts should be word processed. Times New Roman font at 12 pitch should be used, with generous margins and full double spacing throughout. Each line should be numbered by using the line numbering facility within the word processing package.

Papers should normally comprise:

1. A Summary of the findings presented in the paper and the conclusions drawn from them. Authors may, if they wish, suggest not more than four Keywords that should follow the summary.
2. A brief Introduction stating the purpose of the paper.
3. A concise account of the Materials and Methods used. Authors should note that appropriate positive and negative controls should be performed for all experimental techniques and the nature of these controls should be described with the methodology.
4. A record of the Results. Systeme Internationale (S.I.) units should be used.
5. A Discussion of the significance of the results.
6. Any necessary Acknowledgments for assistance. All contributors who do not meet the criteria for authorship as defined above should be listed in an acknowledgments section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance. Finally, the acknowledgments section should include a declaration concerning Funding and any Role of the Funding Source. Authors should declare the role of study sponsors, if any, in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.
7. A Conflict of Interest statement. All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Reference Style

References to published work cited in the text, in alphabetical order. The form should be:

Durand S, Murphy C, Zhang Z, Alexandersen S (2008) Epithelial distribution and replication of foot-and-mouth disease virus RNA in infected pigs. *Journal of Comparative Pathology*, **139**, 86-96.

Where a reference has more than five authors, please give the first five authors followed by et al.

Beuermann C, Beck J, Schmelz U, Dunkelberg H, Schütz E et al. (2009) Tissue calcium content in piglets with inguinal or scrotal hernias or cryptorchidism. *Journal of Comparative Pathology*, **140**, 182-186.

In the text, references to publications by three or more authors should be given in the style "Jones et al." on each occasion.

Titles of books must be given in full with publisher, place of publication and edition if other than first, e.g. Dellman HD (1998) Endocrine system. In: *Textbook of Veterinary Histology*, 5th Edit., HD Dellman, J Eurell, Eds., Lippincott, Williams and Wilkins, Philadelphia, pp. 287-302.

PhD theses should be cited as: Allenspach K (2002) *Chronic Enteropathies in Dogs - Research into the Pathogenesis, Diagnosis and Treatment*. PhD Thesis, University of Berne.

Graphical Abstracts

The Journal will publish a 'graphical abstract' in the on-line version of the Table of Contents for each issue of the Journal. Graphical abstracts comprise a single image (that may or may not be one of the figures in a paper) that encapsulates the subject of the paper. The image may be accompanied by a single sentence of text (of no more than 50 words) that describes the key message of the paper. Graphical abstracts will not be published in the print or on-line versions of the actual paper. Graphical abstracts are optional, but where authors would like to include such an abstract the image and proposed sentence must be submitted with a revised manuscript. The sentence may be modified by the Editor-in-Chief.

Tabulated Material

Tables require captions and should be self-explanatory. Each column should have a heading that accurately describes all entries beneath. Tables should be submitted on separate sheets and designed to fit into the type area of one printed page or less. Authors should consult a recent copy of the Journal and follow as closely as possible the format of tables therein.

Illustrative Material

All illustrative material must be of high quality. Text figures (i.e., diagrams, charts, graphs), should bear lettering, numbers and symbols large enough to be legible after sizing to the journal pages. The figures will be inserted in the text at appropriate places. Authors may wish to have several illustrations grouped into a composite plate. If so, they should submit a sketch plan of the suggested layout but not electronically group the photographs as this work will be undertaken by the Publisher. Such composite blocks should be of the same proportions as the page of the Journal. Where the author wishes to draw attention to particular features by means of arrows or lettering, these should be superimposed electronically on the photographs. **No charge will be made for a reasonable number of figures or for the use of colour for photographic illustrations if, in the Editor's opinion, it enhances the presentation of results.** The maximum page area available for blocks is 23 x 16.9 cm. Figures designed to span one or both columns on a page should be 8.2 cm or 16.9cm wide, respectively.

Legends to all illustrations submitted should be shown separately and, where appropriate, should state the stain and magnification. The latter should be given in the form of a magnification bar inserted directly onto the image.

The following formats can be used to submit figures electronically: EPS; TIFF (minimum resolution of 300 dpi for colour and halftones, 1000 dpi for bitmapped line drawings and 500 dpi for combination halftone/line drawing); DOC/XLS/PPT (if figures are created in any Microsoft Office application please supply "as is"). For a detailed guide on electronic artwork please visit our website <http://www.elsevier.com/artworkinstructions>.

Use of Copyright Material

If excerpts from other copyrighted works are included, the Author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by Authors in these cases: contact Elsevier's Rights Department, Oxford, UK: phone (+1) 215 239 3804 or +44(0)1865 843830, e-mail healthpermissions@elsevier.com. Requests may also be completed online via <http://www.elsevier.com/permissions>.

Material in unpublished letters and manuscripts is also protected and must not be published unless permission has been obtained.

Essential Title Page Information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae.
- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a superscript symbol immediately after the author's name and in front of the appropriate address. The hierarchy of symbols used by this Journal may be seen by consulting a recent issue. Provide the full postal address of each affiliation, including the country name.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, the current affiliation of that author may be indicated in the Acknowledgments section of the manuscript.

Formatting of funding sources

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Data visualization

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions [here](#) to find out about available data visualization options and how to include them with your article.

Supplementary material

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

Data linking

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Mendeley Data

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

Data statement

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher on initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*): <http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

Proofs

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to [download the free Adobe Reader](#), version 9 (or higher). Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the [Adobe site](#).

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and scan the pages and return via e-mail. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints and PDF files

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, exclusive copyright in the paper shall be assigned to the Publisher. In consideration for the assignment of copyright, the Publisher will supply 25 offprints of each paper or a PDF file of the article via e-mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use. Further paper offprints may be ordered at extra cost at the proof stage.

Author's Rights

As an author you (or your employer or institution) may do the following:

- make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use
- make copies and distribute such copies (including through e-mail) of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically, e.g., via an e-mail list or list server)
- post a pre-print version of the article on Internet websites including electronic pre-print servers, and to retain indefinitely such version on such servers or sites
- post a revised personal version of the final text of the article (to reflect changes made in the peer review and editing process) on your personal or institutional website or server, with a link to the journal homepage (on elsevier.com)
- present the article at a meeting or conference and to distribute copies of the article to the delegates attending such a meeting
- for your employer, if the article is a 'work for hire', made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company use (e.g., training)
- retain patent and trademark rights and rights to any processes or procedure described in the article
- include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially)
- use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of your article in the journal)
- prepare other derivative works, to extend the article into book-length form, or to

otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).